CVS Stock Price Today (October 2026) — CVS Health Corporation Analysis & Key Metrics 2026-10-07
CVS Health Corporation (CVS) is trading at $87.95, up 1.76% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $116.28 (32.2% upside).
- Volatility is low (23.40% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (7.10% YoY) alongside competitive pressures in the Healthcare Plans space.
CVS Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
CVS Health Corporation - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $174.83B
P/E Ratio
Forward P/E: 11.04
Revenue Growth
Year over Year
Analyst Target
+32.2% upside potential
Key Investor Questions About CVS
What investors need to know before buying
Based on current market data, CVS presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 45.58)
- Fundamentals say: Looking solid (debt and growth supportive)
CVS's growth trajectory depends on its ability to expand within the Healthcare Plans sector while managing margin pressures.
- Future growth will depend on performance in core Healthcare Plans operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for CVS investors include debt exposure and competitive dynamics in the Healthcare Plans industry.
- $76.31B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Healthcare Plans.
52-Week Trading Range
Over the past year, CVS stock traded between $69.51 and $110.68 and currently trades in the middle of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 23.40% annualized volatility and β=0.10, the stock exhibits low sensitivity to market moves—making CVS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
New retail theft scam hits Walmart, Target, and CVS
Learn how to protect yourself from this growing problem.
Wall Street Analysts Think CVS Health (CVS) Is a Good Investment: Is It?
According to the average brokerage recommendation (ABR), one should invest in CVS Health (CVS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
What Should CVS Stock Investors Be Watching Now?
If you own CVS Health (CVS), the primary focus shifts from 2026 execution toward potential headwind variables heading into 2027. Management raised its 2026 earnings outlook on its fiscal Q2 2026 call in August. It also gave an early read on 2027, a quarter sooner than usual. One warning in that read came with no number. Over the past three months, the shares lost 15.2%, while the S&P 500 gained 5.0%. What is the 2027 problem CVS would not put a number on.
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vet group CVS says portrayal of industry ‘disappointing’ amid reforms
The company also announced its first acquisition in the UK days after the conclusion of the Competition and Markets Authority probe.
CVS Group H2 Earnings Call Highlights
CVS Group (LON:CVSG) reported full-year revenue growth of 5.9% to £712.8 million and adjusted EBITDA growth of 5.1% to £141.5 million, as all three divisions contributed to growth despite softer market conditions late in the year. Chief Executive Officer Richard Fairman said the company delivered r
Here’s What Strengthened CVS Health (CVS) in Q2
Polaris Capital Management, an investment management company, released its second-quarter 2026 investor letter for “Global Equity Strategy”. The letter can be downloaded here. Global markets delivered strong gains during the quarter, supported by an AI-driven earnings rally despite elevated interest rates, inflation concerns, and geopolitical uncertainty. Polaris Global Equity Composite (net of fees) returned 13.26% […]
CVS Health (CVS) Stock May Be Undervalued Despite Oncology Authorization Expansion
CVS Health has delivered a 36.9% share price gain over the past three years, even after a recent pullback. This puts fresh focus on whether that climb still lines up with what the business earns. With earnings in the spotlight and the stock giving back some ground in recent weeks, the key issue for you is whether today's valuation is properly grounded in its profit power. The 36.9% return over three years raises the question of how much of that move reflects lasting earnings strength versus...
CVS vs. CAH: Which Healthcare Services Stock Is the Better Pick Now?
CVS Health and Cardinal Health are benefiting from healthcare growth, but differences in performance, valuation and targets shape the outlook.
Haleon Turns to Weight-Loss Drug Users for its Next U.S. Growth Opportunity
Haleon plc (NYSE:HLN) is finding a new growth opportunity in the expanding U.S. population using GLP-1 weight-loss drugs such as Wegovy and Zepbound. According to Reuters, the company has been placing products that can address GLP-1-related side effects in both its normal store locations and dedicated GLP-1 sections at CVS. That strategy has produced an […]
Explore More Analysis for CVS
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 4, 2026 (before the open)
Frequently Asked Questions
Common investor questions about CVS Health Corporation
CVS Health Corporation (CVS) is currently trading at $87.95. The RSI (14-day) is at 45.6, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $116.28 implies 32.2% upside from current levels. Volatility is moderate at 23.4% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for CVS Health Corporation (CVS): The trailing P/E ratio is 25.21, which is in line with broader market averages. The forward P/E is 11.04, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.25, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 1.53. Price-to-Sales is 0.30. Valuation should be compared to Healthcare Plans industry peers for context, as different sectors trade at different multiples.
Based on 25 analysts covering CVS, the consensus price target is $116.28. This represents a 32.2% upside from the current price of $87.95. The range spans from a low target of $103.00 to a high target of $148.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, CVS Health Corporation (CVS) pays a dividend with a current yield of approximately 3.02%. The annualized dividend rate is $2.66 per share. The payout ratio is 70.2%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was Oct 22, 2026.
Key risks for CVS Health Corporation (CVS) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Healthcare Plans sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is CVS Health Corporation's (CVS) current debt and financial health profile: Total debt stands at $76.31B. The debt-to-equity ratio is 0.96x, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 0.87, which is below 1.0 and may indicate short-term liquidity concerns. The quick ratio is 0.62. The company holds $13.96B in cash and equivalents. Free cash flow is positive at $8.08B, providing a cushion for debt servicing and shareholder returns.